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Abstract
Background: We reported increased levels of Phosphatidyl Inositol synthase (PI synthase), (enzyme that catalyses 
phosphatidyl inositol (PI) synthesis-implicated in intracellular signaling and regulation of cell growth) in smokeless 
tobacco (ST) exposed oral cell cultures by differential display. This study determined the clinical significance of PI 
synthase overexpression in oral squamous cell carcinoma (OSCC) and premalignant lesions (leukoplakia), and identified 
the downstream signaling proteins in PI synthase pathway that are perturbed by smokeless tobacco (ST) exposure.
Methods: Tissue microarray (TMA) Immunohistochemistry, Western blotting, Confocal laser scan microscopy, RT-PCR 
were performed to define the expression of PI synthase in clinical samples and in oral cell culture systems.
Results: Significant increase in PI synthase immunoreactivity was observed in premalignant lesions and OSCCs as 
compared to oral normal tissues (p = 0.000). Further, PI synthase expression was significantly associated with de-
differentiation of OSCCs, (p = 0.005) and tobacco consumption (p = 0.03, OR = 9.0). Exposure of oral cell systems to 
smokeless tobacco (ST) in vitro confirmed increase in PI synthase, Phosphatidylinositol 3-kinase (PI3K) and cyclin D1 
levels.
Conclusion: Collectively, increased PI synthase expression was found to be an early event in oral cancer and a target 
for smokeless tobacco.
Background
Five percent of all cancers occur in the head and neck,
with over 500,000 cases reported annually worldwide,
and mortality rate of about 50% [1-3]; approximately half
of these occur in the oral cavity [4]. Head-and-neck can-
cer sites are readily amenable to clinical examination, yet
a lack of suitable molecular markers for early detection
and risk assessment is clearly reflected by the fact that
more than 50% of all oral squamous cell carcinoma
(OSCC) patients have advanced disease at the time of
diagnosis [1,3,5,6]. Indeed, the five-year survival rates of
OSCC patients are in general poor (about 50% overall)
and the prognosis of advanced OSCC cases has not
improved much over the past three decades [3,5]. Epide-
miological evidence shows a correlation between use of
smokeless tobacco (ST) and lesions of the oral cavity as
well as with incidence of oral cancer [7-9]. OSCCs are
often preceded by clinically evident oral lesions (OLs),
often leukoplakia, and the risk of multiple cancers is 5-10
times greater in patients with OSCCs preceded by leuko-
plakia [10]. These OLs are reported to be more common
in chewing tobacco related oral cancer in India [11].
Intense efforts are being directed towards developing
accurate predictors of clinical outcome using high
throughput techniques such as differential display-
reverse transcription PCR (DD), cDNA microarrays and
proteomics to assess global gene/protein expression pat-
terns in head and neck cancer [12-15]. In search of such
novel molecular targets, our laboratory reported
increased levels of phosphatidyl inositol synthase (PI Syn-
thase) or CDP-diacylglycerol-inositol 3-phosphatidyl
transferase (CDIPT) transcripts in cell cultures from a
human oral lesion (AMOL), exposed to ST extracts using
DD [16], providing the rationale for in-depth investiga-
tion of biological and clinical significance of its expres-
sion in oral cancer.
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PI Synthase (PIS) (EC 2.7.8.11) is a 24-kDa membrane-
bound enzyme, which catalyzes the last step in the de
novo biosynthesis of phosphatidylinositol (PI) by catalyz-
ing the condensation of CDP-diacylglycerol and myo-
inositol to form PI and CMP. PI is involved in protein
membrane anchoring, and is the precursor for the second
messengers- inositol-tri-phosphate and diacylglycerol
(DG). These ubiquitous second messengers function
downstream of many G protein-coupled receptors and
tyrosine kinases regulating cell growth, calcium metabo-
lism, and PKC activity. The biological role of PI is of con-
siderable interest due to the involvement of PI and its
phosphorylated derivatives in intracellular signal trans-
duction. Phosphatidylinositol 3-kinase (PI3K) catalyses
the phosphorylation of PI in the 3-OH position of the
inositol ring. The PI3K pathway regulates various cellular
processes, such as proliferation, growth, apoptosis and
cytoskeletal rearrangement [17,18].
Herein, we determined the effect of ST on the expres-
sion PI Synthase and its downstream targets PI3K and
cyclinD1 in oral cell systems. Further, we investigated the
clinical significance of PI Synthase expression in oral can-
cer using immunohistochemistry.
Methods
Cell culture
Human head and neck squamous carcinoma cell lines,
HSC2, SCC-4 and cell culture from an oral lesion (OL),
AMOL [19], were grown in monolayer cultures in Dul-
becco's modified eagle medium (DMEM) and Ham F-12
(DMEM-F12) (Sigma, MO) supplemented with 10% fetal
bovine serum (FBS), 2.5 mM L-glutamine, 1× sodium
pyruvate (supplied as 100× stock with a concentration of
11,004 mg/L), 1 mM NEAA (non-essential amino acids),
100 μg/ml streptomycin and 100 U/ml penicillin in a
humidified incubator (5% carbon-dioxide, 95% air) at
37°C as described previously [19].
Treatments with Smokeless Tobacco Extract
Aqueous extracts of ST were prepared and standardized
from batch to batch by measuring the nicotine content as
described by us previously [19]. Cells (1000 cells/well)
were plated in 96 well plates and allowed to grow for 24 h
in complete medium. After 24 h, cells were treated with
different concentrations (1-1000 μg/ml range) of ST for
different time intervals 4, 12, 24, 48, 72 and 120 h, with
STE replenished every 24 h. Cell viability was assessed
using MTT assay as described earlier [19]. Cells were
treated with ST (10 μg/ml, 48 hrs) [20,21] and harvested
thereafter for western blotting/RT-PCR analysis/immun-
ofluorescence.
Western blotting
Whole cell lysates were prepared from untreated (con-
trol) and ST-treated AMOL, HSC2 and SCC-4 cells. Pro-
tein concentrations were determined using Bradford
reagent (Sigma) and equal amounts of proteins from
untreated and treated cells were resolved on 10% sodium
dodecyl sulphate (SDS)-polyacrylamide gels. The pro-
teins were then electro-transferred onto polyvinylidened-
ifluoride (PVDF) membrane. After blocking with 10%
non-fat milk in Tris-buffered saline (TBS, 0.1 M, pH =
7.4), blots were incubated with anti-PI Synthase antibody
(a kind gift from Dr. Jackowski, St. JudeChildren's hospi-
tal, Tennesee, Memphis) or anti PI-3kinase or anti-cyclin
D1 antibody (Santa Cruz Biotechnology Inc., Santacruz,
CA) (dilution 1:200) at 4°C overnight. Protein abundance
of α-tubulin served as a control for protein loading, and
was determined with mouse monoclonal anti-α-tubulin
antibody (Santa Cruz Biotechnology, CA). Membranes
were incubated with secondary antibody, HRP-conju-
gated goat/mouse anti-IgG (Dako CYTOMATION, Den-
mark), at an appropriate dilution in 1% BSA, for 2 h at
r o o m  t e m p e r a t u r e .  A f t e r  e a c h  s t e p  b l o t s  w e r e  w a s h e d
thrice with Tween (0.1%)-Tris-buffered saline (TTBS).
Protein bands were detected by enhanced chemilumines-
cence method (ECL, Amersham, Buckinghamshire, UK)
on XO-MAT film.
Confocal laser scan microscopy
Cells (AMOL and HSC2) grown on coverslips were
treated with ST (10 μg/ml, 48 hrs) in DMEM-F12
medium supplemented with 2% FBS at 37°C and pro-
cessed for confocal laser scan microscopy as described by
us [21,22].
Tissue specimens
This study was approved by Human Ethics Committee of
All India Institute of Medical Sciences, New Delhi, India.
For immunohistochemical analysis surgically resected
tissues or biopsy specimens from OSCCs, OLs and nor-
mal oral tissues were obtained from Surgical Oncology
Unit of Dr. B.R. Ambedkar Institute Rotary Cancer Hos-
pital, All India Institute of Medical Sciences, New Delhi,
India, with prior consent of the patients. The clinical and
pathological data recorded included clinical tumor stage,
site of the lesion, histopathological differentiation, age,
gender and, tobacco and alcohol consumption habits in a
pre-designed performa as described by us previously [23].
Clinicopathological characteristics of patients
Twenty one OSCC patients, ranging in age from 29 to 75
years were enrolled in this study. The diagnosis was based
on clinical examination and histopathological analysis of
the tissue specimens. The tumors were histologically
graded as well, moderately or poorly differentiated SCCs.
Twenty oral lesions were included in this study. The his-
topathological assessment scoring based on the architec-
tural and cytological changes of epithelial dysplasia as
described in the WHO classification and recently
reviewed [24]. Oral lesions/leukoplakia (13 cases) were
classified in two groups: (i) OLs with no dysplasia, (ii)Kaur et al. BMC Cancer 2010, 10:168
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OLs with dysplasia. Seven tissues taken from a distant
site of OSCCs (with histologically confirmed normal oral
epithelium hither to referred to as oral normal tissues)
were also evaluated for PI Synthase protein expression.
Tissue Microarray Immunohistochemistry
Oral squamous cancer Tissue Microarray (TMA) with 60
oral tissue sections (IMT-01250) was procured from
Imgenex India Ltd (Bhubaneshwar, Orissa, India). Of the
60 oral tissue sections in TMA, 49 were OSCCs, 8 were
oral lesions and 3 were non-malignant oral tissues. In
addition, paraffin embedded sections (5 μm thickness) of
human oral tissue specimens (21 OSCCs, 12 oral lesions
and 7 non-malignant oral tissues) were stained with
hematoxylin and eosin for histopathological analysis, and
immunostaining was done on serial sections individually
as described previously by Arora et al. [23]. The TMA
slide and the individual tissue sections were de-paraf-
finized by baking at 62°C for 1 hour in vertical orientation
and rehydrated prior to antigen retrieval. Thereafter,
antigen retrieval was carried out using a microwave oven
in 0.01 M-citrate buffer, pH 6.0. Endogenous peroxidase
activity was blocked by incubating sections in methanol
containing hydrogen peroxide (0.3%, v/v) for 20 min.
Non-specific binding was blocked with 1% (w/v) BSA in
PBS for 1 h and incubated with anti-PI Synthase antibody
(1:200 dilution) for 16 h at 4°C. The primary antibody was
detected using biotinylated secondary antibody and per-
oxidase labeled Streptavidin complex using Dako LSAB
plus kit (Dako Labs, Glostrup, Denmark) and diamin-
obenzidine (DAB) as chromogen.
Positive criterion for immunohistochemical staining
The immunopositive staining was evaluated in randomly
selected five non-overlapping areas of the tissue sections
with more than 80% epithelial cells. PI Synthase cytoplas-
mic immunoreactivity was classified into five categories,
defined as follows: (0), l immunostaining in <10% cells;
(+1), immunostaining in 10-30% cells; (+2), immunos-
taining in 30-50% cells; (+3), immunostaining in 50-70%
cells and (+4), immunostaining in >70% of the cells show-
ing cytoplasmic staining. Intensity was graded into four
categories, defined as follows: (0), no detectable immu-
nostaining or basal immunostaining; (+1) mild; (+2)
moderate and (+3) intense immunostaining. The final
score was calculated by adding the percentage positivity
and intensity of staining scores (range 0-7). The immuno-
histochemical investigation was blind, i.e. the slides were
coded and pathologist did not have prior knowledge of
the local tumor burden, lymphonodular spread and grad-
ing of the OSCCs while scoring the immunoreactivity.
Statistical analysis
The immunohistochemical data were subjected to statis-
tical analysis using SPSS 10.0 software (Chicago). Box
plot was prepared to determine the distribution of total
score of PI Synthase protein expression in normal oral tis-
sues, OLs and OSCCs. The performance of a diagnostic
variable can be quantified by calculating the area under
the ROC (receiver operating characteristic) curve. A
graph of sensitivity against 1-specificity is called ROC
curve. Sensitivity of a diagnostic test is the proportion of
patients for whom the outcome is positive that is cor-
rectly identified by the test. Specificity is the proportion
of patients for whom the outcome is negative that are cor-
rectly identified by the test. The ideal test would have an
area under the ROC curve of 1, whereas a random guess
would have an area under the ROC curve of 0.5. A better
predictive power is attributed to a diagnostic variable as it
approaches 1. ROC curve was plotted for PI Synthase for
normal vs. OPLs, and normals Vs OSCCs using the final
score obtained as described above. Sensitivity and speci-
ficity were calculated and quantified using receiver oper-
ating characteristic (ROC) analyses. Based on sensitivity
and specificity values for PI Synthase, a cut-off ≥ 3 was
defined as positive criterion for PI Synthase immunopos-
itivity for statistical examination. The relationships
between PI Synthase expression and clinicopathological
parameters was tested in univariate analysis by Chi-
Square and Fisher's exact test Two sided p-values were
calculated and p ≤ 0.05 was considered to be significant.
Results
To determine the biological significance of PI Synthase,
we investigated the effect of ST on induction of this
enzyme using oral cancer cell lines and oral epithelial cell
cultures [19].
Smokeless Tobacco activates PI Synthase in oral epithelial 
cell cultures
To determine the optimal dose and duration for ST treat-
ment, AMOL and HSC-2 cells were treated with different
concentrations of ST ranging from 1 μg/ml to 1000 μg/ml
for varying time periods ranging from 4 h to 120 h. Cell
viability was measured by MTT assay. HSC-2 cells
showed 25% increase in cell proliferation at 10 μg/ml con-
centration of ST after 48 h and 60% increase in cell prolif-
eration at 10 μg/ml concentration of ST after 72 h.
AMOL cells showed 20% increase in cell proliferation at
10 μg/ml concentration of ST after 48 h. Since higher
doses were toxic for AMOL and HSC-2 cells, we chose 10
μg/ml of ST as the optimal dose for assessing the changes
in protein expression levels upon enhanced cell prolifera-
tion. AMOL cells [19] were treated with 10 μg/ml of ST
for varying time points. Untreated (control) AMOL cells
expressed basal levels of PI Synthase (Figure 1). Treat-
ment of AMOL cells with ST showed increase in PI Syn-
thase expression within 6 h; while 2 fold enhanced
expression was observed in 48 h (Figure 1). Hence, 10 μg/Kaur et al. BMC Cancer 2010, 10:168
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ml ST for 48 h was chosen for further experiments in oral
cells. PI Synthase expression was analysed in AMOL and
HSC-2 cells treated with ST (10 μg/ml) for 48 h by immu-
nocytochemistry using a confocal microscope. Increased
cytoplasmic expression of PI Synthase protein was
observed in ST treated AMOL and HSC-2 cells as com-
pared to the untreated control cells which expressed only
basal levels of PI Synthase protein (Figures 2 and 3
respectively).
Smokeless Tobacco induces PI3K and Cyclin D1 expression 
in oral cell cultures
Basal expression of PI3K was observed in both AMOL
and HSC-2 cells (Figures 2 and 3 respectively). Treatment
of cells with ST resulted in increased cytoplasmic expres-
sion of PI3-K protein (Figures 2 and 3 respectively) and
cyclin D1 (Figures 2 and 3 respectively) in both cell types
as compared to the untreated control cells, suggesting
that ST induced PI Synthase expression, is accompanied
by the induction of PI3-K and cyclin D1 in cultures estab-
lished form OLs and OSCCs.
The immunostaining findings were corroborated by
western blot analysis: untreated AMOL, HSC-2 and SCC-
4 cells expressed basal levels of PI Synthase protein (Fig-
ure 4, lane Untreated), while ST treatment resulted in
increased expression of PI Synthase protein in AMOL
(1.9 folds; Figure 4, lane ST), HSC-2 cells (2 folds; Figure
4, lane ST) and SCC-4 cells (2 folds; Figure 4, lane ST).
A 65 kDa band of PI3K protein was detected in cyto-
plasmic extracts of untreated AMOL, HSC-2 and SCC-4
cells (Figure 4). ST treatment increased the levels of PI3K
protein in AMOL (1.8 folds), HSC-2 (2.1 folds) and SCC-
4 (2 folds) cells (Figure 4). Further, exposure to ST
resulted in increased expression of cyclin D1 protein in
AMOL (2.4 folds), HSC-2 (2 folds) and SCC-4 cells (1.9
folds) as compared to the untreated control cells (Figure
4).
Figure 2 Confocal micrographs showing the expression of PI Synthase, PI-3 Kinase and Cyclin D1 in AMOL cells after treatment with ST. 
Cells grown on coverslips were treated with ST (10 μg/ml) for 48 h and immunolabelled with respective antibodies followed by FITC conjugated sec-
ondary antibody (Green fluorescence) and nuclei were counterstained with PI (red fluorescence). Original Magnification × 200.
Figure 1 Western blot analysis of PI Synthase in whole cell ex-
tracts of AMOL cells. Cells were treated with 10 μg/ml of ST for vary-
ing time period. ST treated and untreated control cells protein extracts 
were resolved on SDS-PAGE gel, transferred on PVDF membrane and 
immunolabelled with PI synthase antibody, and developed using ECL 
as described in methodology section. Western blot of a control protein 
namely α-tubulin was used for comparison.Kaur et al. BMC Cancer 2010, 10:168
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Tissue microarray (TMA) and Immunohistochemical analysis  of PI Synthase expression in normal oral tissues, OLs and 
Figure 3 Confocal micrographs showing the expression of PI Synthase, PI-3 Kinase and Cyclin D1 in HSC-2 cells after treatment with ST. 
Cells grown on coverslips were treated with ST (10 μg/ml) for 48 h and immunolabelled with respective antibodies followed by FITC conjugated sec-
ondary antibody (Green fluorescence) and nuclei were counterstained with PI (red fluorescence). Original Magnification × 200.
Figure 4 Representative immunoblots using whole cell extracts for PI Synthase, PI3-Kinase and Cyclin D1 expression in AMOL, HSC-2 and 
SCC-4 cells. ST treated (ST) and untreated control cells were immunolabelled with respective antibodies and developed using ECL. Western blot of a 
control protein namely α-tubulin was used for comparison.Kaur et al. BMC Cancer 2010, 10:168
http://www.biomedcentral.com/1471-2407/10/168
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OSCCs and clinical correlations
Immunohistochemical analysis of PI Synthase was per-
formed in individual sections of 21 OSCCs, 13 OLs and 7
histologically normal oral tissues. In addition, immuno-
histochemical analysis of PI Synthase was performed in
OSCCs in a TMA format (Figure 4). Histologically
proven normal oral tissue showed no detectable expres-
sion of PI Synthase protein (Figure 5). Cytoplasmic
immunostaining was observed in OLs with no dysplasia
(Figure 5). Intense cytoplasmic PI Synthase immunos-
taining was observed in dysplastic and OSCC lesions
(Figure 5).
The results of immunohistochemical analysis of PI Syn-
thase expression in normal oral tissues (10), OLs (20), and
OSCCs (70); their correlation with clinicopathological
parameters and tobacco consumption habits of the
patients are summarized in Table 1. PI Synthase protein
was localized predominantly in cytoplasm of epithelial
cells. PI Synthase expression was observed in 16/20 (80%)
OLs and 61/70 (87%) OSCCs. Increased expression of PI
Synthase protein was observed in OLs and OSCCs as
compared to normal (histologically non-malignant) oral
tissues as shown in the Box plot analysis in Figure 6. Sig-
nificant increase in PI Synthase expression was observed
in OLs with no dysplasia, dysplasia and OSCC (p =
0.000). In OSCC patients, PI Synthase expression was sig-
nificantly associated with tumor dedifferentiation
(WDSCCs vs. MDSCCs and PDSCCs; p = 0.005) and
tobacco consumption habits (p = 0.03). Figure 7 depicts
25-kDa band of PI Synthase protein in representative
normal oral tissues, OLs and OSCCs obtained by western
blot analysis.
Evaluation of PI Synthase as a potential biomarker
Receiver Operating Characteristic (ROC) analysis was
used to determine the potential of PI Synthase as a bio-
marker for diagnosis of leukoplakia and OSCCs. The
area-under-the-curve (AUC) values were 0.882 and 0.964
for normal versus OLs (Figure 8a) and OSCCs (Figure
8b), respectively indicating that PI Synthase may have the
potential as a diagnostic biomarker for leukoplakia and
OSCCs.
Figure 5 Immunohistochemical analysis of PI Synthase protein in representative oral tissues and Tissue microarray sections i: Zoomed im-
ages of ii; ii: Tissue microarray sections; iii:Oral tissues. Histologically normal tissue showing no detectable immunoreactivity; OLs tissue section 
without and with dysplasia depicting cytoplasmic staining; OSCC showing cytoplasmic staining.Kaur et al. BMC Cancer 2010, 10:168
http://www.biomedcentral.com/1471-2407/10/168
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Discussion
This study, to our knowledge, is the first report demon-
strating overexpression of PI Synthase, PI3-K and cyclin
D1 in ST treated cells from oral lesions and oral cancer.
Analyzing clinical specimens from oral leukoplakic
lesions without dysplasia, with dysplasia and OSCCs, we
provide the first evidence of increased expression of PI
Synthase in early stages of oral precancer and cancer and
its correlation with tumor dedifferentiation and tobacco
consumption.
High PI Synthase activity has been observed in src- and
erbB2-transformed cells regulated by tyrosine kinase [25];
moreover, PI synthesis could be stimulated by addition of
mitogenic growth factors and serum in quiescent normal
rat kidney (NRK) cells. Herein, we demonstrated that in
addition to these factors exposure to tobacco may be
responsible for increased levels of PI Synthase. The bio-
logical and clinical significance of PI Synthase overex-
pression in human cancers remains unknown. However,
PI Synthase has been shown to be essential for progres-
Figure 6 Box-Plot analysis. Box plots showing distribution of total immunostaining scores of PI Synthase protein determined by immunohistochem-
istry in paraffin-embedded sections of normal oral tissues, OLs and OSCCs. The vertical axis gives the total immunostaining score, obtained as de-
scribed in the Methods section. Box plots showed increased expressions of PI Synthase in OSCCs with a median score (bold horizontal line) of 5 (range 
3--6, as shown by vertical bars), as compared to non-malignant (histologically normal) oral tissues with a median score of 0.
Figure 7 Representative western blot for PI Synthase protein in 
oral tissues. normal oral tissues (lane N1, N2); OPLs (lane P1, P2) and 
OSCCs (lane C1, C2) depicting α-tubulin used as a control proteinKaur et al. BMC Cancer 2010, 10:168
http://www.biomedcentral.com/1471-2407/10/168
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Table 1: Analysis of PI Synthase protein expression in normal oral tissues, OLs and OSCCs: Correlation with 
clinicopathological parameters and tobacco consumption habits
Clinicopathological parameters Total Cases PI Synthase cytoplasmic positivity
Nn ( % )
Normal Oral tissues (N) 10 0
OLs 20 16 80
Differentiation
OLs w/o dysplasia 15 11 73
Dysplasia 5 5 100
Mild 2 2
Moderate 2 2
Severe 1 1
^Habits
^Non Tobacco consumer 22
^Tobacco consumer 10 8
#Tobacco chewer 9 8
#Khaini (Tobacco with lime) 4 4
#Gutkha 2 3
#Betel Quid with tobacco 5 4
#Tobacco smoking 4 4
#Alcohol 3 3
OSCCs 70 61 87
Differentiationa
WDSCC 25 19 76
MDSCC 40 38 95
PDSCC 5 4 80
^Habitsb
^Non Tobacco consumer 42
^Tobacco consumer 17 17
#Tobacco chewer 16 5
#Khaini (Tobacco with lime) 14 14
#Gutkha - -
#Betel Quid with tobacco 2 2
#Tobacco smoking 4 4
#Alcohol 4 3
#Overlapping habits; ^cases excluding TMA
a:WDSCC Vs MDSCC + PDSCC (p = 0.005); b: tobacco consumer Vs non-consumer (p = 0.03, OR = 9.0)Kaur et al. BMC Cancer 2010, 10:168
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sion through G1  phase of cell cycle [26], mainly by
increasing the cellular levels of cyclins D1 and E [27]. Pre-
vious studies [25,28,29] have shown that inhibitors of PI
Synthase, inostamycin and δ-hexachloro-cyclohexane
inhibit PI synthesis and blocked cell cycle progression in
the G1  or S phase respectively. Inostamycin caused
decrease in the cellular levels of cyclins D1 and E [25] and
suppressed the invasion ability by reducing productions
of matrix metalloproteinase-2 and -9 and cell motility in
HSC-4 tongue carcinoma cell line [30].
Hence, we propose that increased PI Synthase expres-
sion could play a role in cell transformation through the
increased expression of cyclin D1, and possibly other
growth-enhancing effects. PI Synthase increased the cel-
lular levels of Akt kinase in serum-stimulated quiescent
NIH3T3 cells, decreased doubling time and potentiated
colony formation in soft agar [27]. Since the over expres-
sion of PI Synthase in NIH3T3 cells increased PI synthe-
sis and the amounts of PIP-2 and PIP-3, it is possible that
PI Synthase overexpression also enhances cellular levels
of PIP-2 and PIP-3, which, together with serum, cause
increased activation of Akt kinase. The PI3-K/Akt path-
way not only regulates the transcriptional activity of
cyclin D1, but also increases it accumulation by inactivat-
ing glycogen synthase kinase-3 (GSK3), which targets
cyclin D1 for proteasomal degradation. Since PI Synthase
overexpression enhances Akt kinase activation, this could
explain the increased expression of the cyclin D1 protein.
West et al. [31] showed that tobacco carcinogen (NNK) -
induced cellular transformation and increased the activa-
tion of phosphatidylinositol 3'-kinase/Akt pathway in
vitro and in vivo in lung tumorigenesis. Zheng et al. [32]
demonstrated that nicotine induced PI3-K overexpres-
sion in lung cancer cells. Taken together, it suggests that
upregulation of PI Synthase by ST may be one of the
mechanisms by which ST exerts its effects on the PI-3
kinase pathway and other proteins involved in cellular
proliferation such as cyclin D1 (Figure 9).
Immunohistochemical analysis of PI Synthase was per-
formed in an oral cancer tissue microarray and few indi-
vidual clinical samples of OLs, OSCCs and normal oral
tissues. Significant increase in PI Synthase expression in
lesions without dysplasia, dyplasias and OSCCs, suggests
it to be an early event that occurs prior to development of
malignancy. A salient finding of our study was the associ-
ation of tobacco consumption with overexpression of PI
Synthase in OSCCs. These clinical findings suggested
that PI Synthase might be plausible molecular target of
tobacco. Besides, PI3-K, has been implicated in the devel-
opment and progression of numerous neoplasias includ-
ing OSCCs [33,34]. Stahl et al. [35] suggested PI3-K as a
marker of malignancy and tumor invasion and a potential
target for pharmacological intervention in Head and
Neck cancers.
Figure 8 Receiver operating characteristic curves of PI Synthase.- a) normal vs OLs; b) normal vs OSCCs.Kaur et al. BMC Cancer 2010, 10:168
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Conclusions
In conclusion, our in vitro studies showed increased PI
Synthase, Cyclin D1 and PI3-K expression on exposure to
ST in oral cell systems. In clinical samples, increased PI
Synthase expression was found to be an early event in
oral tumorigenesis, and is sustained during the develop-
ment and progression of OSCC and is associated with
tobacco consumption. These findings underscore its vali-
dation as a candidate diagnostic biomarker in oral cancer.
Large-scale studies are warranted to further evaluate PI
Synthase's potential as an indicator of progression risk in
leukoplakia and a role in development and progression
during early stages oral tumorigenesis.
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